Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response.

Tytuł:
PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response.
Autorzy:
Liu L; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; Institutes of Physical Science and Information Technology, Anhui University, Hefei, China.
Hou J; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Xu Y; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Qin L; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Liu W; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Zhang H; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Li Y; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Chen M; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Deng M; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Zhao B; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Hu J; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Zheng H; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Li C; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Meng S; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Institute of Microbiology, Beijing, China.; University of Chinese Academy of Sciences, Beijing, China.
Źródło:
PloS one [PLoS One] 2020 Jul 06; Vol. 15 (7), pp. e0228302. Date of Electronic Publication: 2020 Jul 06 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
B7-H1 Antigen/*metabolism
Hepatitis B virus/*immunology
Interferon-alpha/*pharmacology
Interferon-gamma/*pharmacology
STAT1 Transcription Factor/*metabolism
T-Lymphocytes/*immunology
Up-Regulation/*drug effects
Animals ; Antibodies, Monoclonal/therapeutic use ; B7-H1 Antigen/chemistry ; B7-H1 Antigen/genetics ; B7-H1 Antigen/immunology ; Binding Sites ; Cell Line ; Hepatitis B/drug therapy ; Hepatitis B/veterinary ; Hepatitis B Surface Antigens/blood ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Transgenic ; Programmed Cell Death 1 Receptor/metabolism ; Promoter Regions, Genetic ; STAT1 Transcription Factor/chemistry ; T-Lymphocytes/metabolism
References:
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7. (PMID: 19088198)
Hepatol Int. 2019 Mar;13(2):113-124. (PMID: 30600480)
Med Mol Morphol. 2009 Sep;42(3):138-42. (PMID: 19784739)
Mol Oncol. 2015 Aug;9(7):1312-23. (PMID: 25841765)
J Hepatol. 2019 Nov;71(5):900-907. (PMID: 31306680)
Hepatology. 2013 Jan;57(1):13-22. (PMID: 22806943)
J Virol. 2013 Jan;87(1):137-47. (PMID: 23055569)
Nat Rev Immunol. 2012 Feb 24;12(3):201-13. (PMID: 22362353)
Gastroenterology. 2016 Mar;150(3):684-695.e5. (PMID: 26684441)
J Immunol. 2014 Oct 15;193(8):3835-41. (PMID: 25281753)
Trends Immunol. 2017 Aug;38(8):542-557. (PMID: 28579323)
Nat Immunol. 2005 Sep;6(9):873-9. (PMID: 16116467)
Lancet Infect Dis. 2007 Dec;7(12):804-13. (PMID: 18045563)
Antiviral Res. 2015 Oct;122:69-81. (PMID: 26275801)
Eur J Immunol. 2010 Mar;40(3):654-63. (PMID: 20077405)
J Hepatol. 2006 Oct;45(4):520-8. (PMID: 16876901)
J Exp Med. 2016 May 30;213(6):1079-93. (PMID: 27139489)
J Hepatol. 2017 Jan;66(1):228-233. (PMID: 27423427)
Chemosphere. 2016 Feb;145:68-76. (PMID: 26688241)
Hepatology. 2011 May;53(5):1494-503. (PMID: 21360567)
J Hepatol. 2012 Jun;56(6):1239-46. (PMID: 22326467)
J Immunol. 2007 Mar 1;178(5):2714-20. (PMID: 17312113)
J Virol. 2013 Feb;87(4):2193-205. (PMID: 23221562)
Vaccine. 2011 Aug 26;29(37):6342-51. (PMID: 21600951)
Cancer Gene Ther. 2009 May;16(5):453-61. (PMID: 19096445)
Nat Med. 2015 Apr;21(4):327-34. (PMID: 25799228)
PLoS Pathog. 2013;9(7):e1003490. (PMID: 23853599)
J Virol. 2007 Apr;81(8):4215-25. (PMID: 17287266)
J Leukoc Biol. 2018 Mar;103(3):565-575. (PMID: 28848042)
Hepatology. 2004 Nov;40(5):1062-71. (PMID: 15486925)
PLoS One. 2013 Jun 11;8(6):e65588. (PMID: 23776506)
J Hepatol. 2019 Jun;70(6):1103-1113. (PMID: 30826436)
Hepatology. 2009 Nov;50(5):1625-37. (PMID: 19739236)
Clin Exp Hepatol. 2019 Sep;5(3):256-264. (PMID: 31598564)
Gastroenterology. 2014 May;146(5):1193-207. (PMID: 24412289)
J Leukoc Biol. 2004 Feb;75(2):163-89. (PMID: 14525967)
Gastroenterology. 2010 Feb;138(2):682-93, 693.e1-4. (PMID: 19800335)
J Hepatol. 2020 Jan;72(1):45-56. (PMID: 31499130)
Trends Immunol. 2011 Mar;32(3):97-103. (PMID: 21227751)
J Hepatol. 2014 Dec;61(6):1212-9. (PMID: 25016223)
Cancer Immunol Immunother. 2018 Feb;67(2):271-283. (PMID: 29090321)
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:132-7. (PMID: 23855309)
PLoS Pathog. 2014 Jan;10(1):e1003856. (PMID: 24391505)
Mol Immunol. 2008 Aug;45(13):3567-72. (PMID: 18585785)
Cell Rep. 2017 May 9;19(6):1189-1201. (PMID: 28494868)
Rev Med Virol. 2020 Mar;30(2):e2094. (PMID: 31825155)
Front Immunol. 2019 Jun 06;10:1319. (PMID: 31244857)
Front Immunol. 2018 Mar 19;9:472. (PMID: 29616020)
Immunity. 2004 Mar;20(3):327-36. (PMID: 15030776)
Vaccine. 2013 Jan 7;31(3):545-52. (PMID: 23149267)
J Viral Hepat. 2019 Jul;26 Suppl 1:5-31. (PMID: 31380584)
Science. 2002 May 31;296(5573):1653-5. (PMID: 12040185)
Blood. 2010 Aug 19;116(7):1124-31. (PMID: 20472834)
Gastroenterology. 2016 Jan;150(1):194-205. (PMID: 26416327)
Substance Nomenclature:
0 (Antibodies, Monoclonal)
0 (B7-H1 Antigen)
0 (Hepatitis B Surface Antigens)
0 (Interferon-alpha)
0 (Programmed Cell Death 1 Receptor)
0 (STAT1 Transcription Factor)
82115-62-6 (Interferon-gamma)
Entry Date(s):
Date Created: 20200707 Date Completed: 20200907 Latest Revision: 20200907
Update Code:
20240105
PubMed Central ID:
PMC7337294
DOI:
10.1371/journal.pone.0228302
PMID:
32628668
Czasopismo naukowe
Programmed death ligand 1 (PD-L1) has been recently shown to be a major obstacle to antiviral immunity by binding to its receptor programmed death 1 (PD-1) on specific IFN-γ producing T cells in chronic hepatitis B. Currently, IFN-α is widely used to treat hepatitis B virus (HBV) infection, but its antiviral effect vary greatly and the mechanism is not totally clear. We found that IFN-α/γ induced a marked increase of PD-L1 expression in hepatocytes. Signal and activators of transcription (Stat1) was then identified as a major transcription factor involved in IFN-α/γ-mediated PD-L1 elevation both in vitro and in mice. Blockage of the PD-L1/PD-1 interaction by a specific mAb greatly enhanced HBV-specific T cell activity by the gp96 adjuvanted therapeutic vaccine, and promoted HBV clearance in HBV transgenic mice. Our results demonstrate the IFN-α/γ-Stat1-PD-L1 axis plays an important role in mediating T cell hyporesponsiveness and inactivating liver-infiltrating T cells in the hepatic microenvironment. These data raise further potential interest in enhancing the anti-HBV efficacy of IFN-α and therapeutic vaccines.
Competing Interests: The authors acknowledge materials support from Beijing Combio Company and Beijing Tiantan Biological Products Company. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies